Xencor, Inc Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount
Xencor, Inc (XNCR) had Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount of $100.00 thousand as of 2022-06-30, per its 10-Q filed 2022-08-03.
Discontinued › Notes › Investments › Debt and Equity Securities
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount · last filed 2022-08-03
- 2022-06-30: Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount $100.00K.
- 2021-06-30: Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount $0.00.
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount |
|---|---|
| 2022-06-30 | $100.00K 10-Q · filed 2022-08-03 |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |